Advertisement

Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in São Paulo, Brazil

Published:December 23, 2022DOI:https://doi.org/10.1016/j.msard.2022.104488

      Highlights

      • The estimated prevalence of anti-AQP4 antibody positive neuromyelitis optica spectrum disorder (NMOSD) is relatively high in the city of São Paulo.
      • The estimated prevalence of MOG antibody associated disease (MOGAD) is relatively low in the city of São Paulo.

      Abstract

      Background

      Numerous studies addressed the prevalence of multiple sclerosis, but prevalence studies of NMOSD and, particularly, MOGAD are scarce. We aimed to estimate the prevalence of NMOSD and MOGAD in the city of São Paulo, based on the known prevalence of MS.

      Methods

      In this observational study, we determined the total number of patients with central nervous system demyelinating disease on regular follow-up in a university referral center in São Paulo, from May 2019 to May 2021 according to the diagnosis of multiple sclerosis (MS), NMOSD and MOGAD using the current diagnostic criteria for these diseases. We used the MS: NMOSD and MS: MOGAD ratios to estimate the ratio of these diseases in São Paulo, Brazil.

      Results

      We identified 968 patients with MS, 133 patients with AQP4 positive NMOSD, and 28 patients with MOGAD. We found the MS: NMOSD ratio of 7,28 and the MS: MOGAD ratio of 34,57. We estimated a prevalence of 2,1 per 100,000 inhabitants for NMOSD and of 0,4 per 100,000 inhabitants for MOGAD.

      Conclusion

      The prevalence of NMOSD is high in São Paulo, but the prevalence of MOGAD is low when compared with the prevalence found in most of the studies reported to date.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Bruijstens, Wong, Pelt, n.d. HLA association in MOG-IgG–and AQP4-IgG–related disorders of the CNS in the Dutch population. Neurology.

        • Callegaro D.
        • Goldbaum M.
        • Morais L.
        • Tilbery C.P.
        • Moreira M.A.
        • Gabbai A.A.
        • Scaff M.
        The prevalence of multiple sclerosis in the city of São Paulo, Brazil, 1997.
        Acta Neurol. Scand. 2001; 104: 208-213
        • Fujihara K.
        • Cook L.J.
        Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
        Curr. Opin. Neurol. 2020; 33: 300-308
        • Guimaraães Brum D.
        • Barreira A.A.
        • dos Santos A.C.
        • Kaimen-Maciel D.R.
        • Matiello M.
        • Costa R.M.
        • Saloun Deghaide N.H.
        • Silva Costa L.
        • Louzada-Junior P.
        • Beserra Diniz P.R.
        • Comini-Frota E.R.
        • Mendes-Junior C.T.
        • Donadi E.A.
        HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis.
        Mult. Scler. 2010; 16: 21-29
        • Lana-Peixoto M.A.
        • Talim N.C.
        • Pedrosa D.
        • Macedo J.M.
        • Santiago-Amaral J.
        Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil.
        Mult. Scler. Relat. Disord. 2021; 50102807
        • Marignier R.
        • Hacohen Y.
        • Cobo-Calvo A.
        • Pröbstel A.-.K.
        • Aktas O.
        • Alexopoulos H.
        • Amato M.-.P.
        • Asgari N.
        • Banwell B.
        • Bennett J.
        • Brilot F.
        • Capobianco M.
        • Chitnis T.
        • Ciccarelli O.
        • Deiva K.
        • De Sèze J.
        • Fujihara K.
        • Jacob A.
        • Kim H.J.
        • Kleiter I.
        • Lassmann H.
        • Leite M.-.I.
        • Linington C.
        • Meinl E.
        • Palace J.
        • Paul F.
        • Petzold A.
        • Pittock S.
        • Reindl M.
        • Sato D.K.
        • Selmaj K.
        • Siva A.
        • Stankoff B.
        • Tintore M.
        • Traboulsee A.
        • Waters P.
        • Waubant E.
        • Weinshenker B.
        • Derfuss T.
        • Vukusic S.
        • Hemmer B.
        Myelin-oligodendrocyte glycoprotein antibody-associated disease.
        Lancet Neurol. 2021; 20: 762-772
        • O'Connell K.
        • Hamilton-Shield A.
        • Woodhall M.
        • Messina S.
        • Mariano R.
        • Waters P.
        • Ramdas S.
        • Leite M.I.
        • Palace J.
        Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK.
        J. Neurol. Neurosurg. Psychiatry. 2020; 91: 1126-1128
        • Orlandi R.
        • Mariotto S.
        • Gajofatto A.
        Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy.
        Mult. Scler. Relat. Disord. 2022; 63103884
        • Pena S.D.J.
        • Santos F.R.
        • Tarazona-Santos E.
        Genetic admixture in Brazil.
        Am. J. Med. Genet. C Semin. Med. Genet. 2020; 184: 928-938
      2. Saadat, Hojjati, Khatir, Ahangar, n.d. Epidemiology of Multiple Sclerosis: a Narrative Review. Int. J. High Risk Behav. Addict.

        • Sabel C.E.
        • Pearson J.F.
        • Mason D.F.
        • Willoughby E.
        • Abernethy D.A.
        • Taylor B.V.
        The latitude gradient for multiple sclerosis prevalence is established in the early life course.
        Brain. 2021; 144: 2038-2046
        • Sato D.K.
        • Callegaro D.
        • Lana-Peixoto M.A.
        • Waters P.J.
        • de Haidar Jorge F.M.
        • Takahashi T.
        • Nakashima I.
        • Apostolos-Pereira S.L.
        • Talim N.
        • Simm R.F.
        • Lino A.M.M.
        • Misu T.
        • Leite M.I.
        • Aoki M.
        • Fujihara K.
        Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
        Neurology. 2014; 82: 474-481
        • Thompson A.J.
        • Banwell B.L.
        • Barkhof F.
        • Carroll W.M.
        • Coetzee T.
        • Comi G.
        • Correale J.
        • Fazekas F.
        • Filippi M.
        • Freedman M.S.
        • Fujihara K.
        • Galetta S.L.
        • Hartung H.P.
        • Kappos L.
        • Lublin F.D.
        • Marrie R.A.
        • Miller A.E.
        • Miller D.H.
        • Montalban X.
        • Mowry E.M.
        • Sorensen P.S.
        • Tintoré M.
        • Traboulsee A.L.
        • Trojano M.
        • Uitdehaag B.M.J.
        • Vukusic S.
        • Waubant E.
        • Weinshenker B.G.
        • Reingold S.C.
        • Cohen J.A.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        Lancet Neurol. 2018; 17: 162-173
        • Wingerchuk D.M.
        • Banwell B.
        • Bennett J.L.
        • Cabre P.
        • Carroll W.
        • Chitnis T.
        • de Seze J.
        • Fujihara K.
        • Greenberg B.
        • Jacob A.
        • Jarius S.
        • Lana-Peixoto M.
        • Levy M.
        • Simon J.H.
        • Tenembaum S.
        • Traboulsee A.L.
        • Waters P.
        • Wellik K.E.
        • Weinshenker B.G.
        • International Panel for NMO Diagnosis
        International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
        Neurology. 2015; 85: 177-189